Home Capital Broker's Calls

Monetisation of TalkMed’s stem cell treatment for cancer will have to wait

PC Lee
PC Lee10/2/2017 04:32 PM GMT+08  • 2 min read
Monetisation of TalkMed’s stem cell treatment for cancer will have to wait
SINGAPORE (Oct 2): RHB is maintaining its “buy” call on TalkMed with lower 69 cents target price despite seeing huge potential in stem cells as a way of treatment, particularly for cancer.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (Oct 2): RHB is maintaining its “buy” call on TalkMed with lower 69 cents target price despite seeing huge potential in stem cells as a way of treatment, particularly for cancer.

Cellular therapy for oncology is one of the most exciting discoveries in recent years. The latest US Food and Drug Administration (USFDA)-approved gene therapy product – chimeric antigen receptor (CAR) T-cells for blood cancers – has been priced at US$475,000 per treatment ($647,261 per treatment).

Mesenchymal stem cells (MSCs), usually found in bone marrow, are currently used in regenerative medicine and therapy overseas for aesthetics and other purposes.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.